Your browser doesn't support javascript.
loading
Long-term protection at 20-31 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community.
Ma, Jing-Chen; Wu, Zhi-Wei; Zhou, Hai-Song; Gao, Zhao; Hao, Zhi-Yong; Jin, Fei; Zhang, Yan-Hong; Li, Min-Jie; Wang, Feng; Li, Qi; Bi, Sheng-Li; Zhao, Yu-Liang.
Afiliación
  • Ma JC; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Wu ZW; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Zhou HS; Institute for Hepatitis, Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
  • Gao Z; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Hao ZY; Institute for Hepatitis, Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
  • Jin F; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Zhang YH; Institute for Hepatitis, Zhengding County Center for Disease Control and Prevention, Zhengding, People's Republic of China.
  • Li MJ; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Wang F; Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Li Q; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
  • Bi SL; Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China.
  • Zhao YL; Institute for Vaccine Clinical Research, Hebei Province Center for Disease Control and Prevention, Shijiazhuang, People's Republic of China.
Hum Vaccin Immunother ; 16(1): 16-20, 2020.
Article en En | MEDLINE | ID: mdl-31339432
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra Hepatitis B / Hepatitis B / Anticuerpos contra la Hepatitis B Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Hum Vaccin Immunother Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Vacunas contra Hepatitis B / Hepatitis B / Anticuerpos contra la Hepatitis B Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male País/Región como asunto: Asia Idioma: En Revista: Hum Vaccin Immunother Año: 2020 Tipo del documento: Article